Inventiva announces completion of patient visits for its Phase IIb clinical study with lanifibranor in NASH

NEXT STORY
OSE Immunotherapeutics and Servier Amend the Global Licensing Option Agreement for IL-7R Antagonist OSE-127 in Autoimmune Diseases
PREV STORY
Predictive Technology Group Addresses Use of Mesenchymal Stem Cells in Treatment of Secondary Issues Related to Coronavirus
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

MATEON’S GLOBAL STUDY FOR ARTEMISININ INTERVENTION AGAINST COVID-19 CLEARED FOR PATIENT ENROLLMENT IN INDIA.

author_avatar
NASDAQ Market News

Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma

author_avatar
NASDAQ Market News

Bellerophon Therapeutics Announces First Patient Treated in Phase 3 Clinical Study of INOpulse® Inhaled Nitric Oxide Therapy for COVID-19

author_avatar
NASDAQ Market News